Asuragen Overview

  • Founded
  • 2005
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 144
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $215M
Latest Deal Amount

Asuragen General Information

Description

Developer of molecular diagnostic products designed to optimize patient management in oncology and genetic diseases. The company presents a wide range of kits and assays for genetic sequencing as well as cancer monitoring, enabling the medical community to enhance treatment outcomes through accurate data.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Outcome Management (Healthcare)
Other Pharmaceuticals and Biotechnology
Decision/Risk Analysis
Parent Company
Primary Office
  • 2150 Woodward Street
  • Suite 100
  • Austin, TX 78744
  • United States
+1 (512) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Asuragen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 13-Apr-2021 $215M 000.00 00000 Completed Generating Revenue
7. Debt - PPP 27-Apr-2020 00.000 000.00 Completed Generating Revenue
6. Later Stage VC (Series C) 20-Mar-2013 00.00 000.00 00000 Completed Generating Revenue
5. Grant 30-Mar-2012 00.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 11-Aug-2011 000 000.00 000.00 Completed Generating Revenue
3. Grant 08-Oct-2008 00.00 000.00 Completed Startup
2. Early Stage VC (Series B) 10-Dec-2007 $18.5M $67.4M 000.00 Completed Startup
1. Early Stage VC (Series A) 01-Jun-2006 $48.9M $48.9M 000.00 Completed Startup
To view Asuragen’s complete valuation and funding history, request access »

Asuragen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series B 00,000,000 00.000000 00.0 00.0 00 00.0 00.000
Series A 48,895,000 $0.001000 $1 $1 1x $1 55.48%
To view Asuragen’s complete cap table history, request access »

Asuragen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of molecular diagnostic products designed to optimize patient management in oncology and genetic diseases. The
Diagnostic Equipment
Austin, TX
144 As of 2021
000.00
0000 0000-00-00
000000&0 000.00

00000000

d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in rep
0000000000 00000000 (0000000000)
San Diego, CA
000 As of 0000
000.00
0000 0000-00-00
000000&0 000.00

00000000

equat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000000000 000000000
Puteaux, France
000 As of 0000
000.00
0000 0000-00-00
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Asuragen Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioTheranostics Formerly VC-backed San Diego, CA 000 000.00 000000&0 000.00
000000000000 Private Equity-Backed Puteaux, France 000 000.00 000000000000
0000000000 0000000 Formerly VC-backed Cambridge, MA 0000 00000 00000000000
0000 00 0000 Accelerator/Incubator Backed Houston, TX 00 000000&0
000000 000000000 Formerly PE-Backed Codolet, France 000 000000&0
You’re viewing 5 of 16 competitors. Get the full list »

Asuragen Executive Team (18)

Name Title Board Seat Contact Info
Matthew McManus MD President, Chief Executive Officer & Board Member
Lynne Hohlfeld Chief Financial Officer & Senior Vice President, Corporate Development
Matthew Winkler Ph.D Founder and Chairman
Bernard Andruss Ph.D Senior Vice President of Operations and Regulatory Affairs
Gary Latham Ph.D Senior Vice President, Research & Development
You’re viewing 5 of 18 executive team members. Get the full list »

Asuragen Board Members (13)

Name Representing Role Since
Christopher Earl Ph.D Self Board Member 000 0000
David Sargent Self Board Member 000 0000
Deval Lashkari Ph.D Telegraph Hill Partners Board Member 000 0000
Matthew Crawford PTV Healthcare Capital Board Member 000 0000
Matthew McManus MD Asuragen President, Chief Executive Officer & Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

Asuragen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Asuragen Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Growth Capital Fund Venture Capital Minority 000 0000 000000 0
Merck Global Health Innovation Fund Corporate Venture Capital Minority 000 0000 000000 0
PTV Healthcare Capital Venture Capital Minority 000 0000 000000 0
Southwest Middle Market M&A Merchant Banking Firm Minority 000 0000 000000 0
State Of Texas Real Estate Fund Real Estate 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Asuragen Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 01-Jan-2009 00000 00000 00 000 Biotechnology 0000000 0000000 00.0
Mirna Therapeutics 04-Apr-2008 Seed Round 000 Biotechnology 0000000 0000000 00.0
To view Asuragen’s complete investments history, request access »

Asuragen Exits (2)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 000000000000 01-Jan-2009 00000 00000 00 000 Completed
  • 00000000
Mirna Therapeutics 04-Apr-2008 Seed Round 000 Completed
To view Asuragen’s complete exits history, request access »